Annovis Bio Files 8-K
Ticker: ANVS · Form: 8-K · Filed: Jul 10, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $9.00, $7.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Annovis Bio filed an 8-K on 7/10/24 for Reg FD disclosure and financials.
AI Summary
Annovis Bio, Inc. filed an 8-K on July 10, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure or exhibits.
Why It Matters
This 8-K filing indicates Annovis Bio, Inc. is making a regulatory disclosure and providing financial statements and exhibits, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, without immediate indication of significant negative or positive events.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- July 10, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on July 10, 2024.
What is the Commission File Number for Annovis Bio, Inc.?
The Commission File Number for Annovis Bio, Inc. is 001-39202.
What is the I.R.S. Employer Identification No. for Annovis Bio, Inc.?
The I.R.S. Employer Identification No. for Annovis Bio, Inc. is 26-2540421.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive office address for Annovis Bio, Inc. is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-07-10 16:05:43
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
- $9.00 — ants") at a per share exercise price of $9.00 had been exercised between July 8, 2024
- $7.0 million — exercises resulted in gross proceeds of $7.0 million and the issuance of approximately 0.8 m
Filing Documents
- tm2419203d1_8k.htm (8-K) — 26KB
- 0001104659-24-078937.txt ( ) — 197KB
- anvs-20240710.xsd (EX-101.SCH) — 3KB
- anvs-20240710_lab.xml (EX-101.LAB) — 33KB
- anvs-20240710_pre.xml (EX-101.PRE) — 22KB
- tm2419203d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure Annovis Bio, Inc. (the "Registrant") announced today that 0.8 million warrants that were previously issued on November 1st, 2023 ("November Warrants") at a per share exercise price of $9.00 had been exercised between July 8, 2024 and July 9, 2024. The November Warrant exercises resulted in gross proceeds of $7.0 million and the issuance of approximately 0.8 million shares of common stock. Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: July 10, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer